| Assay ID | Title | Year | Journal | Article |
|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID296660 | Inhibition of hamster soluble epoxide hydrolase by radioactive assay | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID1814170 | Metabolic stability in mouse liver recombinant microsomes assessed as parent compound remaining measured after 60 mins in presence of NADP by UPLC-MS/MS analysis | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| From the Design to the |
| AID296666 | Bioavailability in dog at 0.3 mg/kg, po | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID296659 | Inhibition of rat recombinant soluble epoxide hydrolase by fluorescent assay | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID296671 | Half life in dog at 0.3 mg/kg, po or 0.3 mg/kg, iv | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID296655 | Inhibition of human recombinant soluble epoxide hydrolase | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID756119 | Inhibition of recombinant PDGFRalpha (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID755349 | Inhibition of human recombinant soluble epoxide hydrolase using ((3-phenyl-oxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester) as substrate at 1 nM preincubated for 5 mins prior to substrate addition measured after 60 mins by fluorescenc | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides. |
| AID1706976 | Antiinflammatory activity in BALB/c mouse model of carrageenan-induced paw edema assessed as paw thickness at 100 mg/kg, ip pretreated for 1 hr followed by carrageenan challenge and measured after 3 hrs by caliper method (Rvb = 3.61 +/- 0.36 millimeter) | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects. |
| AID1175621 | Inhibition of recombinant purified chicken soluble epoxide hydrolase using fluorescent PHOME as substrate | 2015 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
| Identification of potent inhibitors of the chicken soluble epoxide hydrolase. |
| AID1706963 | Inhibition of recombinant human sEH using PHOME as substrate measured after 15 mins by fluorescence assay | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects. |
| AID1873515 | Antinociceptive activity in carrageenan-induced inflammatory pain Sprague-Dawley rat model assessed as increase in mechanical withdrawal threshold at 50 mg/kg, ip by von-frey filament assay | 2022 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 70 | Synthesis and biological evaluation of new series of benzamide derivatives containing urea moiety as sEH inhibitors. |
| AID1175627 | Inhibition of recombinant purified chicken soluble epoxide hydrolase by FRET-based competitive displacement assay in presence of ACPU | 2015 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
| Identification of potent inhibitors of the chicken soluble epoxide hydrolase. |
| AID756127 | Inhibition of human recombinant soluble epoxide hydrolase assessed as cyano(6-methoxy-naphthalen-2-yl)methyl trans-[(3-phenyloxyran-2-yl)methyl] carbonate conversion to 6-methoxy-2-naphthaldehyde preincubated for 5 mins prior to substrate addition by fluo | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID296664 | AUC in in dog at 0.3 mg/kg, po | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID1706974 | Antiinflammatory activity in BALB/c mouse model of carrageenan-induced paw edema assessed as paw thickness at 100 mg/kg, ip pretreated for 1 hr followed by carrageenan challenge and measured after 2 hrs by caliper method (Rvb = 3.56 +/- 0.29 millimeter) | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects. |
| AID1175625 | Stability in chicken liver microsomes assessed as compound remaining at 1 uM after 30 mins by mass spectrometry | 2015 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
| Identification of potent inhibitors of the chicken soluble epoxide hydrolase. |
| AID756121 | Inhibition of recombinant GSK3alpha (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID296669 | Reduction of LPS-induced blood pressure mouse C57BL/6 at 0.5 mg/kg, po | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID1722863 | Inhibition of recombinant human soluble epoxide hydrolase using CMNPC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay | 2020 | Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
| 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: |
| AID756126 | Inhibition of recombinant ABL-2 (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1814166 | Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco2 cells at 10 uM incubated for 2 hrs treated with Lucifer Yellow by UPLC-MS/MS analysis | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| From the Design to the |
| AID755345 | Competitive inhibition of human recombinant soluble epoxide hydrolase using [3H]-tDPPO as substrate | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides. |
| AID296663 | Inhibition of human sEH by fluorescent assay | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID1833694 | Inhibition of human sEH using cyano(6-methoxynaphthalen-2-yl)methyl((3-phenyloxiran-2-yl)methyl)carbonate as a substrate assessed as reduction in 6-methoxynaphthaldehyde formation by fluorescence microplate reader assay | 2021 | Bioorganic & medicinal chemistry, 12-01, Volume: 51 | Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors. |
| AID592802 | Inhibition of human recombinant COX-2 after 2 mins by fluorescence assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. |
| AID296657 | Solubility in sodium phosphate buffer at pH 7.4 | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID1814168 | Inhibition of human recombinant sEH using CMNPC as substrate incubated for 5 mins by fluorescent based assay | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| From the Design to the |
| AID592801 | Inhibition of ovine COX-1 at 100 uM after 2 mins by fluorescence assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. |
| AID1722866 | Apparent permeability across basolateral to apical side in human Caco-2 cells at 10 uM measured after 2 hrs by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
| 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: |
| AID296667 | Reduction of LPS-induced blood pressure mouse C57BL/6 at 1 mg/kg, po | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID1706971 | Toxicity in BALB/c mouse assessed as effect on paw thickness at 100 mg/kg, ip measured after 1 hr by caliber method (Rvb = 2.64 +/- 0.09 millimeter) | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects. |
| AID1373459 | Inhibition of human FAAH expressed in baculovirus-infected High Five cells S9 fraction using OMP substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID296670 | Tmax in dog at 0.3 mg/kg, po or 0.3 mg/kg, iv | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID1601281 | Inhibition of murine soluble epoxide hydrolase expressed in baculovirus infected Sf21 cells using NEPC as substrate by fluorescence based assay | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
| Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors. |
| AID1722864 | Solubility of the compound in 1% DMSO/99% PBS buffer solution measured after 2 hrs by light scattering based assay | 2020 | Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
| 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: |
| AID756117 | Inhibition of recombinant PDPK-1 (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1706975 | Antiinflammatory activity in BALB/c mouse model of carrageenan-induced paw edema assessed as paw edema at 100 mg/kg, ip pretreated for 1 hr followed by carrageenan challenge and measured after 2 hrs by caliper method relative to control | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects. |
| AID1601280 | Inhibition of recombinant human liver soluble epoxide hydrolase expressed in baculovirus infected Sf21 cells using NEPC as substrate by fluorescence based assay | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
| Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors. |
| AID296662 | Inhibition of dog soluble epoxide hydrolase by radioactive assay | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID1873509 | Inhibition of sEH (unknown origin) at 100 nM relative to control | 2022 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 70 | Synthesis and biological evaluation of new series of benzamide derivatives containing urea moiety as sEH inhibitors. |
| AID296658 | Inhibition of mouse recombinant soluble epoxide hydrolase by fluorescent assay | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID1814174 | Solubility of compound in PBS incubated for 2 hrs | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| From the Design to the |
| AID1814173 | Inhibition of rat recombinant sEH using CMNPC as substrate incubated for 5 mins by fluorescent based assay | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| From the Design to the |
| AID1819953 | Cardioprotective activity in Langendorff-perfused wild-type C57BL/6 mouse heart assessed as increase in heart rate at 3 nM | 2021 | Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
| Combined Cardioprotective and Adipocyte Browning Effects Promoted by the Eutomer of Dual sEH/PPARγ Modulator. |
| AID661400 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra at 10 uM | 2012 | Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
| Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability. |
| AID296665 | Bioavailability in dog at 0.3 mg/kg, iv | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID756125 | Inhibition of recombinant FLT-3 (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID296661 | Inhibition of cat soluble epoxide hydrolase by radioactive assay | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID1706972 | Antiinflammatory activity in BALB/c mouse model of carrageenan-induced paw edema assessed as paw thickness at 100 mg/kg, ip pretreated for 1 hr followed by carrageenan challenge and measured after 1 hr by caliper method (Rvb = 3.51 +/- 0.19 millimeter) | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects. |
| AID1814171 | Metabolic stability in rat liver recombinant microsomes assessed as parent compound remaining measured after 60 mins in presence of NADP by UPLC-MS/MS analysis | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| From the Design to the |
| AID1814178 | Inhibition of human COX-2 | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| From the Design to the |
| AID1175624 | Stability in human liver microsomes assessed as compound remaining at 1 uM after 30 mins by mass spectrometry in presence of NADPH | 2015 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
| Identification of potent inhibitors of the chicken soluble epoxide hydrolase. |
| AID661399 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra | 2012 | Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
| Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability. |
| AID756120 | Inhibition of recombinant PDGFRbeta (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID592803 | Inhibition of human recombinant soluble epoxide hydrolase after 10 mins by fluorescent-based assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. |
| AID1706962 | Inhibition of recombinant human sEH at 100 nM using PHOME as substrate measured after 15 mins by fluorescence assay relative to control | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects. |
| AID1373458 | Inhibition of human recombinant soluble epoxide hydrolase expressed in baculovirus-infected High Five cells S9 fraction using CMNPC substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1706979 | Antiinflammatory activity in BALB/c mouse model of carrageenan-induced paw edema assessed as paw edema at 100 mg/kg, ip pretreated for 1 hr followed by carrageenan challenge and measured after 4 hrs by caliper method relative to control | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects. |
| AID1601283 | Solubility of compound in 1% DMSO : 99% PBS buffer solution at 37 degree C measured after 2 hrs by nephelometer analysis | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
| Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors. |
| AID756122 | Inhibition of recombinant MET (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1814177 | Inhibition of human recombinant LOX-5 preincubated for 10 mins in presence of AA and ATP measured after 20 mins by fluorescent assay | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| From the Design to the |
| AID1175626 | Stability in chicken liver microsomes assessed as compound remaining at 1 uM after 30 mins by mass spectrometry in presence of NADPH | 2015 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
| Identification of potent inhibitors of the chicken soluble epoxide hydrolase. |
| AID1814169 | Metabolic stability in human liver recombinant microsomes assessed as parent compound remaining measured after 60 mins in presence of NADP by UPLC-MS/MS analysis | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| From the Design to the |
| AID1873510 | Inhibition of sEH (unknown origin) | 2022 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 70 | Synthesis and biological evaluation of new series of benzamide derivatives containing urea moiety as sEH inhibitors. |
| AID1857694 | Inhibition of human recombinant sEH | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
| Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors. |
| AID1175623 | Stability in human liver microsomes assessed as compound remaining at 1 uM after 30 mins by mass spectrometry | 2015 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
| Identification of potent inhibitors of the chicken soluble epoxide hydrolase. |
| AID756124 | Inhibition of recombinant FLT-1 (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID756113 | Cytotoxicity against human HuH7 cells by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1601282 | Microsomal stability in human microsomes assessed as parent compound remaining in presence of NADP, glucose-6-phosphate and glucose-6-phosphate dehydrogenase measured after 60 mins by UPLC-MS/MS analysis | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
| Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors. |
| AID592808 | Antiallodynic activity in Sprague-Dawley rat von Frey hair mechanically-stimulated neuropathic pain model assessed as reversal of LPS-induced decrease in paw withdrawal latency at 10 mg/kg, sc administered 60 mins before LPS challenge | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. |
| AID1722867 | Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco-2 cells at 10 uM measured after 2 hrs by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
| 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: |
| AID1601284 | Apparent permeability across apical to basolateral membrane in human Caco2 cells at 10 uM measured after 2 hrs by UPLC-MS/MS analysis | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
| Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors. |
| AID1814175 | Apparent permeability of compound across apical to basolateral side in human Caco2 cells at 10 uM incubated for 2 hrs treated with Lucifer Yellow by UPLC-MS/MS analysis | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| From the Design to the |
| AID755350 | Inhibition of human recombinant soluble epoxide hydrolase using ((3-phenyl-oxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester) as substrate at 10 nM preincubated for 5 mins prior to substrate addition measured after 60 mins by fluorescen | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides. |
| AID1601286 | Efflux ratio of apparent permeability across basolateral to apical membrane over apical to basolateral membrane in human Caco2 cells at 10 uM measured after 2 hrs by UPLC-MS/MS analysis | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
| Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors. |
| AID1706977 | Antiinflammatory activity in BALB/c mouse model of carrageenan-induced paw edema assessed as paw edema at 100 mg/kg, ip pretreated for 1 hr followed by carrageenan challenge and measured after 3 hrs by caliper method relative to control | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects. |
| AID1722865 | Apparent permeability across apical to basolateral side in human Caco-2 cells at 10 uM measured after 2 hrs by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
| 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: |
| AID1814176 | Cytotoxicity against human SH-SY5Y cells assessed as lethal dose measured after 24 hrs by propidium iodide staining based fluorescent assay | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| From the Design to the |
| AID1814167 | Apparent permeability of compound across basolateral to apical side in human Caco2 cells at 10 uM incubated for 2 hrs treated with Lucifer Yellow by UPLC-MS/MS analysis | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| From the Design to the |
| AID1706978 | Antiinflammatory activity in BALB/c mouse model of carrageenan-induced paw edema assessed as paw thickness at 100 mg/kg, ip pretreated for 1 hr followed by carrageenan challenge and measured after 4 hrs by caliper method (Rvb = 3.60 +/- 0.12 millimeter) | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects. |
| AID1551776 | Inhibition of soluble epoxide hydrolase (unknown origin) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome. |
| AID1819948 | Cardioprotective activity in Langendorff-perfused wild-type C57BL/6 mouse heart assessed as increase in heart rate at 30 nM | 2021 | Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
| Combined Cardioprotective and Adipocyte Browning Effects Promoted by the Eutomer of Dual sEH/PPARγ Modulator. |
| AID756116 | Inhibition of full length recombinant c-RAF (unknown origin) using MEK1 as substrate after 1 hr by luminescence assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID756123 | Inhibition of recombinant FGFR-2 (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID661405 | Inhibition of human recombinant soluble epoxide hydrolase using CMNPC as substrate assessed as appearance of 6-methoxy-2-naphthaldehyde after 10 mins by fluorescence analysis | 2012 | Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
| Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability. |
| AID1706973 | Antiinflammatory activity in BALB/c mouse model of carrageenan-induced paw edema assessed as paw edema at 100 mg/kg, ip pretreated for 1 hr followed by carrageenan challenge and measured after 1 hr by caliper method relative to control | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects. |
| AID1814172 | Inhibition of mouse recombinant sEH using CMNPC as substrate incubated for 5 mins by fluorescent based assay | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| From the Design to the |
| AID296656 | Metabolic stability in human liver microsomes | 2007 | Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
| Orally bioavailable potent soluble epoxide hydrolase inhibitors. |
| AID1175622 | Solubility of the compound in 0.1 M sodium phosphate buffer at pH 7.4 containing 1% DMSO by turbidity method | 2015 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
| Identification of potent inhibitors of the chicken soluble epoxide hydrolase. |
| AID756118 | Inhibition of recombinant KDR (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1601285 | Apparent permeability across basolateral to apical membrane in human Caco2 cells at 10 uM measured after 2 hrs by UPLC-MS/MS analysis | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
| Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors. |
| AID756112 | Antiproliferative activity against HUVEC after 72 hrs by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID756114 | Cytotoxicity against human HepG2 cells by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1798579 | Mtb EHB Inhibition Assay from Article 10.1016/j.jmb.2008.06.030: \\The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor.\\ | 2008 | Journal of molecular biology, Sep-12, Volume: 381, Issue:4
| The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2014 | Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8
| Structural insights into binding of inhibitors to soluble epoxide hydrolase gained by fragment screening and X-ray crystallography. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |